56. Behcet disease
68 clinical trials, 87 drugs (DrugBank: 31 drugs), 36 drug target genes, 113 drug target pathways
Searched query = "Behcet disease", "Behçet disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02258867 (ClinicalTrials.gov) | November 2014 | 2/10/2014 | Efficacy and Safety Study of Gevokizumab to Treat Behcet's Disease Uveitis | A Randomized-Withdrawal, Double-Masked, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Subjects With Behcet's Disease Uveitis | Behcet's Disease Uveitis | Drug: Placebo;Drug: Gevokizumab | XOMA (US) LLC | NULL | Terminated | 18 Years | N/A | Both | 4 | Phase 3 | United States |
| 2 | EUCTR2012-001125-27-GB (EUCTR) | 15/01/2013 | 12/09/2012 | Efficacy of gevokizumab in the treatment of patients with Behçet's disease uveitis | A randomized, double-masked, placebo-controlled study of the efficacy of gevokizumab in the treatment of patients with Behçet’s Disease uveitisEYEGUARD TM -B | Behçet’s disease uveitis MedDRA version: 18.0;Level: LLT;Classification code 10071139;Term: Behcet's uveitis;System Organ Class: 100000004866;Therapeutic area: Diseases [C] - Eye Diseases [C11] | Product Name: Gevokizumab Product Code: S78989 INN or Proposed INN: gevokizumab Other descriptive name: XOMA 052 | Institut de Recherches Internationales Servier | NULL | Not Recruiting | Female: yes Male: yes | 60 | Phase 3 | Portugal;Hong Kong;Saudi Arabia;Greece;Spain;Turkey;Russian Federation;United Kingdom;Italy;India;France;Brazil;Tunisia;Germany;China;Korea, Republic of | ||
| 3 | EUCTR2012-001125-27-PT (EUCTR) | 04/01/2013 | 13/09/2012 | Efficacy of gevokizumab in the treatment of patients with Behçet's disease uveitis | A randomized, double-masked, placebo-controlled study of the efficacy of gevokizumab in the treatment of patients with Behçet’s Disease uveitis - EYEGUARD TM-B | Behçet’s disease uveitis MedDRA version: 18.0;Level: LLT;Classification code 10071139;Term: Behcet's uveitis;System Organ Class: 100000004866;Therapeutic area: Diseases [C] - Eye Diseases [C11] | Product Name: Gevokizumab Product Code: S78989 INN or Proposed INN: gevokizumab Other descriptive name: XOMA 052 | Institut de Recherches Internationales Servier | NULL | Not Recruiting | Female: yes Male: yes | 44 | Phase 3 | Portugal;Saudi Arabia;Hong Kong;Greece;Spain;Turkey;Russian Federation;United Kingdom;Italy;India;France;Brazil;Tunisia;Germany;China;Korea, Republic of | ||
| 4 | EUCTR2012-001125-27-IT (EUCTR) | 26/11/2012 | 21/09/2012 | Efficacy of gevokizumab in the treatment of patients with Behcet`s disease uveitis | A randomized, double-masked, placebo-controlled study of the efficacy of gevokizumab in the treatment of patients with Behçet’s Disease uveitis. The EYEGUARD B study. - THE EYEGUARD TM B STUDY | Behçet's disease uveitis MedDRA version: 14.1;Level: SOC;Classification code 10021428;Term: Immune system disorders;System Organ Class: 10021428 - Immune system disorders MedDRA version: 14.1;Level: PT;Classification code 10046851;Term: Uveitis;System Organ Class: 10015919 - Eye disorders;Therapeutic area: Diseases [C] - Eye Diseases [C11] | Product Name: GEVOKIZUMAB Product Code: S78989 INN or Proposed INN: GEVOKIZUMAB Other descriptive name: XOMA 052 | INSTITUT DE RECHERCHES INTERNATIONALES SERVIER | NULL | Not Recruiting | Female: yes Male: yes | 110 | Portugal;Saudi Arabia;Hong Kong;Greece;Spain;Turkey;Russian Federation;Italy;United Kingdom;India;Brazil;Tunisia;Germany;China;Korea, Republic of | |||
| 5 | NCT01965145 (ClinicalTrials.gov) | November 2012 | 17/9/2013 | Efficacy of Gevokizumab in the Treatment of Patients With Behçet's Disease Uveitis (EYEGUARD™-B) | A Randomized, Double-masked, Placebo-controlled Study of the Efficacy of Gevokizumab in the Treatment of Patients With Behçet's Disease Uveitis | Behcet's Uveitis | Drug: Gevokizumab;Drug: Placebo | Institut de Recherches Internationales Servier | NULL | Terminated | 18 Years | N/A | All | 84 | Phase 3 | Korea, Republic of;United Kingdom |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | EUCTR2012-001125-27-ES (EUCTR) | 17/10/2012 | 02/10/2012 | Efficacy of gevokizumab in the treatment of patients with Behçet's disease uveitis | A randomized, double-masked, placebo-controlled study of the efficacy of gevokizumab in the treatment of patients with Behçet?s Disease uveitis | Behçet?s disease uveitis MedDRA version: 14.1;Level: LLT;Classification code 10071139;Term: Behcet's uveitis;System Organ Class: 100000004870;Therapeutic area: Diseases [C] - Eye Diseases [C11] | Product Name: Gevokizumab Product Code: S78989 INN or Proposed INN: gevokizumab Other descriptive name: XOMA 052 | Laboratorios Servier S.L. | NULL | Not Recruiting | Female: yes Male: yes | 110 | Portugal;Saudi Arabia;Hong Kong;Greece;Spain;Turkey;Russian Federation;Italy;United Kingdom;India;France;Brazil;Tunisia;Germany;China;Korea, Republic of | |||
| 7 | EUCTR2012-001125-27-GR (EUCTR) | 03/10/2012 | 13/09/2012 | Efficacy of gevokizumab in the treatment of patients with Behçet's disease uveitis | A randomized, double-masked, placebo-controlled study of the efficacy of gevokizumab in the treatment of patients with Behçet’s Disease uveitis | Behçet’s disease uveitis MedDRA version: 15.0;Level: LLT;Classification code 10071139;Term: Behcet's uveitis;System Organ Class: 10021428 - Immune system disorders;Therapeutic area: Diseases [C] - Eye Diseases [C11] | Product Name: Gevokizumab Product Code: S78989 INN or Proposed INN: gevokizumab Other descriptive name: XOMA 052 | Institut de Recherches Internationales Servier | NULL | Not Recruiting | Female: yes Male: yes | 110 | Portugal;Saudi Arabia;Hong Kong;Greece;Spain;Turkey;Russian Federation;Italy;United Kingdom;India;France;Brazil;Tunisia;Germany;China;Korea, Republic of | |||
| 8 | EUCTR2012-001125-27-DE (EUCTR) | 24/09/2012 | 12/09/2012 | Efficacy of gevokizumab in the treatment of patients with Behçet's disease uveitis | A randomized, double-masked, placebo-controlled study of the efficacy of gevokizumab in the treatment of patients with Behçet’s Disease uveitisEYEGUARD TM -B | Behçet’s disease uveitis MedDRA version: 17.1;Level: LLT;Classification code 10071139;Term: Behcet's uveitis;System Organ Class: 100000004866;Therapeutic area: Diseases [C] - Eye Diseases [C11] | Product Name: Gevokizumab Product Code: S78989 INN or Proposed INN: gevokizumab Other descriptive name: XOMA 052 | Institut de Recherches Internationales Servier | NULL | Not Recruiting | Female: yes Male: yes | 44 | Portugal;Saudi Arabia;Hong Kong;Greece;Spain;Turkey;Russian Federation;United Kingdom;Italy;India;France;Brazil;Germany;Tunisia;China;Korea, Republic of |